Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens
Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has the potential to prevent the infection from getting established. This is different from systemic vaccination, which protects against the development of systemic symptoms. The field of mucosal vaccination has seen fewe...
Main Authors: | Farokh Dotiwala, Arun K. Upadhyay |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/10/1585 |
Similar Items
-
Vaccines for Respiratory Viruses—COVID and Beyond
by: Kalpana Rajanala, et al.
Published: (2024-08-01) -
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
by: Farokh Dotiwala, et al.
Published: (2022-09-01) -
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals
by: Najwa D. Aljehani, et al.
Published: (2025-01-01) -
A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates
by: Sarah N. Tedjakusuma, et al.
Published: (2024-01-01) -
Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants
by: Michael J. Moser, et al.
Published: (2023-06-01)